Rosenthal P, Wong V, Ross L A, Kim K S
Department of Pediatrics, University of Southern California School of Medicine, Los Angeles.
J Pediatr Gastroenterol Nutr. 1990 Aug;11(2):201-4. doi: 10.1097/00005176-199008000-00008.
To assess the immunogenicity of HIB vaccines in patients in whom hepatoportoenterostomies were performed for biliary atresia, eight such children received Haemophilus influenzae type b-polyribosylribitol phosphate (HIB-PRP) vaccine and had pre- and postvaccination total serum anti-PRP antibody concentrations determined by radioimmunoassay. Preimmunization anti-PRP antibody levels ranged from less than 0.125 to 0.40 microgram/ml [geometric mean antibody titer (GMT) 0.106 microgram/ml], while postvaccination levels ranged from 0.161 to 1.192 micrograms/ml (GMT = 0.489 microgram/ml). Five children who did not achieve postimmunization anti-PRP antibody levels greater than 1.0 microgram/ml received 15 micrograms of either PRP coupled to diphtheria toxoid (PRP-D) or PRP coupled to an outer membrane protein complex of Neisseria meningitidis group B (PRP-NOMP) conjugate vaccine. Anti-PRP antibody levels 1 month after immunization with HIB conjugate vaccines ranged from 1.51 to 10.35 micrograms/ml (GMT = 3.386 micrograms/ml). Patients with extrahepatic biliary atresia and hepatoportoenterostomies who previously received the HIB-PRP vaccine should be revaccinated with PRP protein conjugate vaccines to ensure adequate protection against H. influenzae type b disease.
为评估在因胆道闭锁接受肝门肠吻合术的患者中B型流感嗜血杆菌疫苗（HIB疫苗）的免疫原性，8名此类儿童接种了b型流感嗜血杆菌-多聚核糖基核糖醇磷酸酯（HIB-PRP）疫苗，并通过放射免疫测定法测定了接种疫苗前后血清中抗PRP抗体的总浓度。免疫前抗PRP抗体水平范围为低于0.125至0.40微克/毫升[几何平均抗体滴度（GMT）为0.106微克/毫升]，而接种疫苗后水平范围为0.161至1.192微克/毫升（GMT = 0.489微克/毫升）。5名接种疫苗后抗PRP抗体水平未超过1.0微克/毫升的儿童接种了15微克的与白喉类毒素偶联的PRP（PRP-D）或与B群脑膜炎奈瑟菌外膜蛋白复合物偶联的PRP（PRP-NOMP）结合疫苗。接种HIB结合疫苗1个月后抗PRP抗体水平范围为1.51至10.35微克/毫升（GMT = 3.386微克/毫升）。先前接种过HIB-PRP疫苗的肝外胆道闭锁和接受肝门肠吻合术的患者应重新接种PRP蛋白结合疫苗，以确保获得足够的保护以预防b型流感嗜血杆菌疾病。
